Expert Opinion on Pharmacotherapy

Papers
(The H4-Index of Expert Opinion on Pharmacotherapy is 19. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
Comprehensive overview of the available pharmacotherapy for the treatment of non-neurogenic overactive bladder in children36
Perspectives on the advances in the pharmacotherapeutic management of Duchenne muscular dystrophy36
The pharmacological treatment and management of hyperhidrosis35
Fixed-dose combination amlodipine–celecoxib for treatment of hypertension and osteoarthritis pain: an up-to-date evaluation32
Antidepressant medications in women aged 40 and older and the risk of fragility fractures: a systematic literature review and meta-analysis30
Rheumatoid arthritis in Latin America: pharmacotherapy and clinical challenges29
Evaluating the safety and efficacy of seladelpar for adults with primary biliary cholangitis28
Bexagliflozin for type 2 diabetes: an overview of the data28
Besifovir dipivoxil maleate: a novel antiviral agent with low toxicity and high genetic barriers for chronic hepatitis B27
Pharmacotherapy developments in autophagy inhibitors for bladder cancer27
Chemotherapy in resectable or potentially resectable colon cancer with liver metastases26
An overview of mineralocorticoid receptor antagonists as a treatment option for patients with heart failure: the current state-of-the-art and future outlook25
Real-world safety and effectiveness of roxadustat in patients with anemia of chronic kidney disease: interim results from a post-marketing surveillance study in Japan24
GnRH agonists and antagonists in therapy of symptomatic uterine fibroids – current roles and future perspectives24
Promising therapies for adults with symptomatic obstructive hypertrophic cardiomyopathy: 2023 and beyond23
A 2023 update on the advancements in the treatment of agitation in Alzheimer’s disease23
Current treatment options for Mycobacterium marinum cutaneous infections22
Efficacy of 3-day versus 5-day aprepitant regimens for long-delayed chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based chemotherapy20
The role of sodium-glucose co-transporter 2 protein inhibitors in heart failure: more than an antidiabetic drug?19
How useful is chemotherapy for atypical and anaplastic meningiomas?19
Resmetirom: the first approved therapy for treating metabolic dysfunction associated steatohepatitis19
Advances in the management of obstructive hypertrophic cardiomyopathy: The role of mavacamten19
0.10324811935425